February 18, 2022

A Bull Market Begets a Bear Market | Midas Letter Daily ft $CYBN

Midas Letter
Midas Letter
A Bull Market Begets a Bear Market | Midas Letter Daily ft $CYBN
/

There’s some blood in the streets as all major indices are down. The S&P 500 fell 2.1% with the Nasdaq sinking 2.9%. The Russian/Ukraine geopolitical instability indicators still concern investors coupled with surging inflation and how the Federal Reserve plans to fight it. But don’t forget, a bull market begets a bear market, and a bear market begets a bull market. So, there is always an opportunity to be found when prices go on sale.

The Fed has been forced into a position of being hawkish because they’ve lost control of inflation. There is one thing that is more important than the wealth effect of stimulus-stimulated markets and that is the possibility that people can’t afford groceries, homes or gasoline.

The Fed has started promoting a 0.25% rate rise for March. The market demand destruction has been tempered by the suddenly soaring cost of mortgages and the rising new home inventory in the United States. As interest rates rise and housing becomes less affordable.

Bitcoin is taking another hammering as its value as a safe haven asset fails decisively in the face of the imminent global conflict. Gold, on the other hand, is up just over $1,900 dollars per ounce. That’s an eight-month high as the deteriorating situation in Ukraine drives safe-haven interest into the metallic standard against which all money has always been measured.

We shift gears from macroeconomic news to bring back Cybin Inc (NEO:CYBN, NYSEAMERICAN:CYBN) CEO Doug Drysdale to talk about the progress the psychedelic company has been making over the last few months.

Cybin is taking the psychedelic molecules you have heard of like MDMA, psilocybin, and DMT and turning them into proprietary therapeutics for mental health disorders like depression and addiction. Psychedelic medicines are gaining traction as more people and investors believe the drugs could revolutionize mental healthcare. With 50+ novel psychedelic molecules in its preclinical pipeline, Cybin has one of the largest psychedelic portfolios in the world.

Transcript

00:00 – Midas Letter Daily
00:56 – Coming Up
01:25 – Audience Questions
01:28 – When will Voxtur Analytics CEO be on the show?
01:44 – Buy $GMG and when?
03:23 – WTI Crude price prediction
03:40 – Biggest risks to market?
05:02 – Major markets charts
05:55 – Fed rate hikes
06:46 – Bitcoin vs gold
07:22 – Commodities (lumber, tin, copper, lithium)
09:07 – Cybin Inc $CYBN CEO Doug Drysdale
19:43 – $CYBN chart & psychedelics market

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.